Health

  • August 06, 2026

    Shein Eyes $40B Valuation Via Hong Kong IPO, More Rumors

    Fast-fashion company Shein is seeking a $40 billion valuation through its Hong Kong initial public offering, betting platform Polymarket is eyeing a new funding round that could value it at $20 billion and Cencora's MWI Animal Health merger with Covetrus faces regulatory scrutiny.

  • August 06, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Tossed By Texas Judge

    A Texas federal court has dismissed compounding pharmacy Strive Specialties Inc.'s antitrust lawsuit against Eli Lilly and Novo Nordisk, finding it failed to allege the companies blocked competition for GLP-1 medications.

  • August 06, 2026

    Judge OKs $35M Teva Deal In Delayed Generic Inhalers Suit

    A Massachusetts federal judge has approved an antitrust settlement that will see Teva Pharmaceuticals pay $35 million to resolve claims that it schemed to delay generic competition for its QVAR asthma inhalers.

  • August 05, 2026

    Product Liability Cases To Watch: Midyear Report

    Social media companies are headed back to court over allegations that their platforms are designed to hook young people, while OpenAI faces claims that ChatGPT has meted out harmful health advice and helped users plan mass shootings. Here's what's on the radar for product liability for the rest of 2026.

  • August 05, 2026

    Drug Cos. Can't Trim Humana's Price-Fix Claims In Bellwether

    A Pennsylvania federal judge on Tuesday denied a bid by a number of generic drug manufacturers to dismiss two antitrust claims brought by health insurer Humana Inc. from an upcoming bellwether trial in long-running antitrust multidistrict litigation, finding they were brought within the statute of limitations.

  • August 05, 2026

    Kansas Judge Permanently Blocks Abortion Care Restrictions

    A Kansas state court has permanently enjoined a slew of restrictions on abortion care, including requirements that providers disclose patients' reasons for seeking an abortion to the state and inform patients about abortion pill "reversal" treatments the court said were "unlikely to be biologically plausible."

  • August 05, 2026

    Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

    Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug Amitiza should be reduced by rebates the drugmaker paid and Medicare subsidies that reduced the health plans' costs.

  • August 05, 2026

    HHS Decertifies Ky. Organ Group Amid Investigation

    After a federal investigation found that a Kentucky organ procurement organization moved forward to recover the organs of a man showing signs of life, the Department of Health and Human Services has announced it's revoking the group's certification. 

  • August 05, 2026

    Aetna, Others Hit Pharma Cos. With Xifaxan Pay-To-Delay Suit

    Health insurance companies Aetna Inc., Health Care Service Corp. and Molina Inc. have sued multiple pharmaceutical companies in Pennsylvania state court in Pittsburgh, alleging that the defendants conspired to delay the release of generic versions of the irritable bowel syndrome drug Xifaxan, in violation of antitrust laws.

  • August 05, 2026

    Mich. Parents Seek $375K In Newborn Blood Spot Case

    A group of Michigan parents has asked a federal judge to award nearly $375,000 in attorney fees and costs after they secured a consent judgment that ended part of the state's newborn blood spot retention program and required the destruction of about 3.4 million samples. 

  • August 05, 2026

    No Coverage For Assisted Living Death, Fla. Panel Says

    A Florida appellate court on Wednesday reversed a judgment that required National Assisted Living Risk Retention Group to provide coverage for a wrongful death suit from a resident's 2012 death, finding no claim was made during the relevant policy period.

  • August 05, 2026

    Fenwick-Led Attovia Therapeutics Prices Upsized $289M IPO

    Early-stage biotechnology company Attovia Therapeutics hit the public markets on Wednesday after it raised $289 million in its upsized initial public offering.

  • August 05, 2026

    Texas Firm Lands $150M HHS Services Deal For Migrant Kids

    The U.S. Department of Health and Human Services said it has entered into a $150 million contract with a small Texas law firm to provide legal services to unaccompanied immigrant children, raising concerns from former subcontractors about the firm's experience with immigration matters.

  • August 05, 2026

    Pa. Court Wipes Out $19M Verdict In Nursing Home Death Suit

    A Pennsylvania appeals court has vacated $19 million in damages, including $15 million in punitive damages, in a suit against nursing home operators and managers over the death of a resident, finding the trial court should have reconsidered damages after negating liability against two of the four defendants.

  • August 05, 2026

    Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls

    Glenmark Pharmaceuticals' generic drug carvedilol, used to treat high blood pressure and congestive heart failure, was misrepresented as therapeutically equivalent to the brand-name drug Coreg but contained undisclosed nitrosamine impurities that changed its strength, quality and safety profile, according to a proposed class action filed Tuesday in Washington federal court.

  • August 05, 2026

    Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs

    A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive's argument that compounded drugs fall outside state "new drug" laws.

  • August 05, 2026

    King & Spalding Hires Crowell Healthcare Consulting Leader

    King & Spalding LLP has announced the hiring of a Crowell & Moring LLP partner who was also the managing director of Crowell Health Solutions, a consulting vertical that his former firm launched four years earlier.

  • August 04, 2026

    TikTok Settles 3 Teen Addiction Suits Before Bellwether Trials

    The company behind TikTok settled three lawsuits brought by young people alleging the social media platform caused them mental health harm, a lawyer for the plaintiffs said Tuesday, although three other social media companies are still scheduled to go to trial in Los Angeles on the claims in October.

  • August 04, 2026

    Colo. Panel Mulls Med Mal Retrial Bid Over Pretrial Meeting

    A Colorado man urged a state appellate court Tuesday to order a new trial in his medical malpractice lawsuit in which jurors sided with his physicians, arguing to a skeptical panel that the defense's ex parte pretrial meeting with his own treating surgeon caused him prejudicial harm.

  • August 04, 2026

    3rd Circ. Won't Give Ex-Olympus Exec Another Go At FCA Suit

    The Third Circuit has declined to revive a whistleblower suit by Olympus Corp.'s former employee who claimed he was fired after reporting FDA regulatory violations, ruling Tuesday that he failed to state a retaliation claim under the False Claims Act since he didn't link his concerns to a reasonable belief that Olympus defrauded the government.

  • August 04, 2026

    Health Provider To Pay $14.1M To Settle False Diagnoses Suit

    A healthcare provider with headquarters in Florida has agreed to pay the federal government $14.1 million to resolve allegations it entered false diagnosis codes to increase the payments it received from the Medicare Advantage program.

  • August 04, 2026

    Healthcare Fraud Task Force Expands To Philly, Charges 19

    Federal and Pennsylvania law enforcement officials on Tuesday announced charges against 19 defendants involved in home care, alleging they bilked Medicare and Medicaid out of funds meant for caregivers and beneficiaries — representing an expansion of the federal crackdown on benefits fraud to Philadelphia.

  • August 04, 2026

    Kirkland, Jones Day Guide P&G's $3.8B Buy Of Thorne

    Procter & Gamble is acquiring supplements company Thorne from L Catterton for $3.8 billion in cash, with Kirkland & Ellis LLP and Jones Day serving as legal advisers in the transaction, the companies announced Tuesday.

  • August 04, 2026

    Fla. High Court Won't Touch Reversal Of $213M 'Maya' Award

    The Florida Supreme Court said Tuesday it would not hear the appeal of a decision that reversed a $213 million judgment against a Florida hospital in favor of Maya Kowalski, the subject of the Netflix documentary "Take Care of Maya."

  • August 04, 2026

    NYC Retirees Ink $53M In Healthcare Copay Class Action

    New York City and EmblemHealth will pay $53 million to resolve a class action complaint covering more than 250,000 Medicare-eligible retirees who alleged the defendants illegally charged $15 copays onto their healthcare costs, according to a preliminary approval motion filed Friday in New York state court.

Expert Analysis

  • Mapping Philly US Atty's White Collar Enforcement Push

    Author Photo

    Attorneys at Blank Rome discuss the U.S. Attorney for the Eastern District of Pennsylvania David Metcalf’s commitments and priorities, survey early results from his first year, and suggest practical action items for companies operating under the office's jurisdiction.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • Steps To Consider As DOJ Launches Fraud Division

    Author Photo

    The establishment this month of the National Fraud Enforcement Division within the U.S. Department of Justice is a significant reorganization that suggests an increase in enforcement activity involving federally funded programs but leaves a number of important questions unanswered, say attorneys at Crowell & Moring.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Opinion

    DOJ Delay Of ADA Web Rule Undermines Equal Access

    Author Photo

    The U.S. Department of Justice's recent decision to delay compliance dates for regulations ensuring accessible government services online benefits no one, as it is long overdue for disabled Americans and doesn't lessen covered entities' legal obligations or litigation risk, say Mark Riccobono at the National Federation of the Blind and Eve Hill at Brown Goldstein.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • The Challenge Of Stabilizing Rural Hospitals On The Brink

    Author Photo

    The outlook for rural hospitals has grown more concerning, as recent policy and regulatory developments are decreasing hospital revenues and increasing the cost of uncompensated care, which may result in additional hospital closures, service reductions, or mergers and acquisitions, say Omur Celmanbet, Kristy Piccinini and Sabiha Quddus at FTI Consulting.

  • Insurer Lessons From 1st Wave Of GenAI Coverage Rulings

    Author Photo

    Several pending cases target the issue of whether generative AI may appropriately replace human professional decision-making, and though each case is still in discovery, the decisions thus far provide insurers with guidance on how courts may view these claims, say attorneys at Simpson Thacher.

  • The Role Of Operational Data In Tech Platform Liability Suits

    Author Photo

    As litigation becomes a de facto substitute for the regulation of major technology platforms, with plaintiffs advancing claims under product liability, public nuisance and consumer protection laws, among others, courts are evaluating how platform systems operate in practice based on large-scale operational data, say attorneys at Brattle.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.